Stephen Basso
Director of Finance/CFO at INNOVIVA, INC.
Net worth: 184 343 $ as of 2024-03-30
Profile
Stephen Basso is currently the Chief Financial Officer at Innoviva, Inc. Prior to this, he was the Vice President-North America Commercial at Alexion Pharmaceuticals, Inc. from 2016 to 2017, and the Chief Financial Officer & Senior VP-Finance at Inozyme Pharma, Inc. from 2020 to 2021.
He also served as the Chief Operating & Financial Officer at Cybrexa, Inc. Mr. Basso holds an MBA from Boston College and an undergraduate degree from Providence College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INNOVIVA, INC.
0.02% | 2024-03-04 | 12,096 ( 0.02% ) | 184 343 $ | 2024-03-30 |
Stephen Basso active positions
| Companies | Position | Start |
|---|---|---|
| INNOVIVA, INC. | Director of Finance/CFO | 2023-08-20 |
Former positions of Stephen Basso
| Companies | Position | End |
|---|---|---|
| INOZYME PHARMA, INC. | Director of Finance/CFO | 2021-05-13 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-04-30 |
Cybrexa, Inc.
 Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
Training of Stephen Basso
| Boston College | Masters Business Admin |
| Providence College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| INOZYME PHARMA, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
- Stock Market
- Insiders
- Stephen Basso
